Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Ronan Le Goffic has a total of 426 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Pathogenicity and immune response of turkey A(H1N2) influenza virus of swine-origin on turkeys and mice

    by Chloé Chavoix, Charlotte Pain-Deloizy, Pascale Massin, Katell Louboutin, Florent Souchaud, Rachel Busson, Carole Guillemoto, Angélina Orosco, Isabelle Pierre, François-Xavier Briand, et al.

    In 2020, a new swine influenza H1 av N2#E genotype emerged in pig farms in France. Shortly after its emergence in swine, this virus was detected in breeding turkey farms, and was responsible of a zoonotic infection. Phylogenetic analyses previously conducted on viral sequences led to the selection of three viruses: the first strain detected in turkeys, resulting from a recent spillover from swine to turkeys (A); a second virus also detected in turkeys and likely adapted to this species (B); and a swine reference strain (C). In the context of species-barrier crossing, the aim of this study was to characterize in vivo these three viruses in an avian model, the breeding turkey, and in a mammalian model, the mouse. Clinical signs, lesions, viral loads, and immune responses were evaluated. In turkeys inoculated experimentally, all three viruses caused similar very mild clinical signs and no viral shedding. In contrast, in mice, virus A caused marked clinical signs associated with mortality, along with a weak inflammatory response. Conversely, virus C caused few clinical signs but showed a more pronounced inflammatory response. Surprisingly, only two nonsynonymous mutations were present between viruses C and A: K189R in PB1 and E233K in HA. Virus B displayed an intermediate profile. There was no difference in genomic load in the lungs among the three viruses, suggesting that the observed differences in pathogenicity were due to the immune response rather than viral replication.

  • Open Access

    A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo

    by Gregory Mathez, Paulo Jacob Silva, Vincent Carlen, Charlotte Deloizy, Clémentine Prompt, Anaïs Hubart, Joana Rocha-Pereira, Marie Galloux, Ronan Le Goffic, Francesco Stellacci, et al.

    Respiratory viruses can cause severe infections, often leading to hospitalization or death, and pose a major pandemic threat. No broad-spectrum antiviral is currently available. However, most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized a modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, and severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In addition, the compound is active against avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad-spectrum activity in ex vivo models of respiratory tissues and in vivo against respiratory syncytial virus and influenza virus, using prophylactic and therapeutic strategies. These findings contribute to the development of future treatments and preventive measures for respiratory viral infections.


  • Open Access

    Cis -aconitate therapy protects against influenza mortality by dual targeting of viral polymerase and ERK/AKT/NF-κB signaling

    by Adeline Cezard, Déborah Brea-Diakite, Virginie Vasseur, Alan Wacquiez, Loic Gonzalez, Ronan Le Goffic, Bruno Da Costa, Delphine Fouquenet, Severine Heumel, Arnaud Machelart, et al.

    Influenza virus poses a significant global health challenge, causing approximately 500,000 deaths annually. Its ability to evade antiviral treatments and vaccine-induced immunity underscores the need for novel therapeutic approaches. Our study identifies cis -aconitate ( cis -aco), a mitochondria-derived metabolite, as a potent dual-action agent against influenza, independently of its metabolic derivative, itaconate. Cis -aco impairs viral polymerase activity, suppressing viral mRNA expression and protein synthesis to inhibit replication across a range of influenza subtypes. This antiviral efficacy is confirmed in ex vivo human airway and lung organotypic models. Beyond its antiviral properties, cis-aco exhibits potent anti-inflammatory effects, disrupting key inflammatory cascades and reducing the secretion of inflammatory mediators. In a mouse model of influenza pneumonia, cis -aco mitigates viral replication, inflammation, and immune cell activation, significantly improving survival. Notably, its efficacy persists even when administered at later stages of infection, when oseltamivir/Tamiflu® is no longer effective. These findings position cis -aco as a promising influenza treatment, combining antiviral and anti-inflammatory benefits within a clinically relevant timeframe.


  • Open Access

    Virus‐Induced Cellular Senescence Causes Pulmonary Sequelae Post‐Influenza Infection

    by Larissa Lipskaia, Lou Delval, Valentin Sencio, Emmanuelle Born, Séverine Heumel, Amal Houssaini, Clara Valentin, Stefano Raviola, Lucie Deruyter, Fabiola Silva Angulo, et al.

    Influenza A virus (IAV) infection causes acute and long‐term lung damage. Here, we used immunostaining, genetic, and pharmacological approaches to determine whether IAV‐induced cellular senescence causes prolonged alterations in lungs. Mice infected with a sublethal dose of H1N1p2009 exhibited cellular senescence, as evidenced by increased pulmonary expression of p16, p21, β‐galactosidase and the DNA damage marker gamma‐H2A.X. Cellular senescence began 4 days post‐infection (dpi) in the bronchial epithelium, then spread to the lung parenchyma by 7 and 28 dpi (long after viral clearance), and then declined by 90 dpi. At 28 dpi, the lungs showed severe remodeling with structural bronchial and alveolar lesions, abrasion of the airway epithelium, and pulmonary emphysema and fibrotic lesions that persisted up to 90 dpi. In mice and nonhuman primates, persistence of senescent cells in the bronchial wall on 28 dpi was associated with abrasion of the airway epithelium. In p16‐ATTAC mice, depletion of p16‐expressing cells with AP20187 reduced pulmonary emphysema and fibrosis and led to complete recovery of the airway epithelium at 28 dpi, indicating a marked acceleration of the epithelial repair process. Treatment with the senolytic drug ABT‐263 also accelerated epithelial repair without affecting pulmonary fibrosis or emphysema. These positive effects occurred independently of viral clearance and lung inflammation at 7 dpi. Finally, AP20187 treatment of p16‐ATTAC mice at 15 dpi led to complete recovery of the airway epithelium at 28 dpi. Thus, virus‐induced senescent cells contribute to the pulmonary sequelae of influenza; targeting senescent cells may represent a new preventive therapeutic option.


  • The prion-family protein Doppel exerts a protective role during influenza virus infection

    by Soraya Dinant, Johan Castille, Charlotte Deloizy, Elise Bruder, Laura Sedano, Nathalie Daniel-Carlier, Bruno Da Costa, Bruno Passet, Vincent Béringue, Amandine Duchesne, et al.

    The cellular form of the prion protein (PrPC), known for its involvement as a misfolded isoform in transmissible spongiform encephalopathies, has recently been identified to exert a protective effect against viral infections. In this study, we explored the role of 2 other prion family members, Shadoo and Doppel, in protection against influenza A virus infection in mice. Lung expression levels of these genes revealed marked differences, with high expression of PrPC, low expression of Doppel, while Shadoo remained undetectable. Mice genetically knocked out for the genes encoding PrPC, Prnp−/− or Doppel, Prnd−/−, showed increased susceptibility to the virus, resulting in elevated morbidity compared with wild-type mice and mice knocked out for Shadoo, Sprn−/−. Unlike previous results observed in Prnp−/− mice, the absence of Doppel does not show enhancing effect on virus replication levels. Histological analysis of lung tissue from Prnd−/− mice revealed no difference in lesion size and severity compared with wild-type mice. However, transcriptomic analysis on day 7 postinfection revealed distinct signatures in Prnd−/− mice, highlighting the role of specific genes associated with polymorphonuclear neutrophil cells. Bronchoalveolar lavages confirmed a substantial neutrophil influx and increased inflammatory markers in the lungs of Prnd−/− mice. Neutrophil depletion experiments demonstrated a direct link between excessive neutrophil influx and increased susceptibility, mitigating pathology and partially restoring a wild-type phenotype in Prnd−/− mice. These findings underscore the complex role of Doppel in modulating the host immune response to influenza virus infection, particularly in regulating neutrophil recruitment and its implications on disease outcomes.

  • Open Access

    A pan-respiratory virus attachment inhibitor with high potency in human airway models and in vivo

    by Gregory Mathez, Paulo Jacob Silva, Vincent Carlen, Charlotte Deloizy, Clémentine Prompt, Anaïs Hubart, Joana Rocha-Pereira, Marie Galloux, Ronan Le Goffic, Francesco Stellacci, et al.

    Respiratory viruses can cause severe infections, including bronchiolitis and pneumonia, often leading to hospitalization or death. Due to their ease of transmission, they are also scrutinized for their pandemic potential. No broad-spectrum antiviral is currently available. However most respiratory viruses use sialic acid or heparan sulfates as attachment receptors. Here, we report the identification of a pan-respiratory antiviral strategy based on mimicking both glycans. We synthesized and characterized a unique modified cyclodextrin that simultaneously mimics heparan sulfate and sialic acid. This novel compound demonstrated broad-spectrum antiviral activity against important human pathogens: parainfluenza virus 3, respiratory syncytial virus, influenza virus H1N1, SARS-CoV-2. Additionally, the compound is active against different avian strains of influenza virus, revealing its importance for pandemic preparedness. The compound retains broad- spectrum activity in ex vivo models of respiratory tissues and in vivo experiments against RSV and Influenza virus, using both prophylactic and therapeutic strategies. These findings represent a significant step forward in the development of future treatments and preventive measures for respiratory viral infections. Significance Statement Following the SARS-CoV-2 pandemic, Influenza A H5N1 has become widespread in poultry and has already begun to spill over into mammals, posing a potential risk for the next pandemic. Indeed, respiratory viruses represent a major threat for future global health crises. Unfortunately, there is a significant lack of broad-spectrum antivirals available for such scenarios. To address this gap, our study developed a single molecule with the capacity to inhibit a wide range of clinically relevant human respiratory viruses including avian strains of influenza virus. This antiviral demonstrated verified efficacy not only in cellular systems but also in human-derived respiratory tissues and animal models.

  • Open Access

    Drug repurposing screen identifies lonafarnib as respiratory syncytial virus fusion protein inhibitor

    by Svenja M. Sake, Xiaoyu Zhang, Manoj Kumar Rajak, Melanie Urbanek-Quaing, Arnaud Carpentier, Antonia P. Gunesch, Christina Grethe, Alina Matthaei, Jessica Rückert, Marie Galloux, et al.

    Respiratory syncytial virus (RSV) is a common cause of acute lower respiratory tract infection in infants, older adults and the immunocompromised. Effective directly acting antivirals are not yet available for clinical use. To address this, we screen the ReFRAME drug-repurposing library consisting of 12,000 small molecules against RSV. We identify 21 primary candidates including RSV F and N protein inhibitors, five HSP90 and four IMPDH inhibitors. We select lonafarnib, a licensed farnesyltransferase inhibitor, and phase III candidate for hepatitis delta virus (HDV) therapy, for further follow-up. Dose-response analyses and plaque assays confirm the antiviral activity (IC50: 10-118 nM). Passaging of RSV with lonafarnib selects for phenotypic resistance and fixation of mutations in the RSV fusion protein (T335I and T400A). Lentiviral pseudotypes programmed with variant RSV fusion proteins confirm that lonafarnib inhibits RSV cell entry and that these mutations confer lonafarnib resistance. Surface plasmon resonance reveals RSV fusion protein binding of lonafarnib and co-crystallography identifies the lonafarnib binding site within RSV F. Oral administration of lonafarnib dose-dependently reduces RSV virus load in a murine infection model using female mice. Collectively, this work provides an overview of RSV drug repurposing candidates and establishes lonafarnib as a bona fide fusion protein inhibitor.


  • Open Access

    Non-Steroidal Estrogens Inhibit Influenza Virus by Interacting with Hemagglutinin and Preventing Viral Fusion

    by Elisa Franzi, Gregory Mathez, Soraya Dinant, Charlotte Deloizy, Laurent Kaiser, Caroline Tapparel, Ronan Le Goffic, Valeria Cagno

    Influenza virus is one of the main causes of respiratory infections worldwide. Despite the availability of seasonal vaccines and antivirals, influenza virus infections cause an important health and economic burden. Therefore, the need to identify alternative antiviral strategies persists. In this study, we identified non-steroidal estrogens as potent inhibitors of influenza virus due to their interaction with the hemagglutinin protein, preventing viral entry. This activity is maintained in vitro, ex vivo, and in vivo. Therefore, we found a new domain to target on the hemagglutinin and a class of compounds that could be further optimized for influenza treatment.


  • Open Access

    An Isolate of Streptococcus mitis Displayed In Vitro Antimicrobial Activity and Deleterious Effect in a Preclinical Model of Lung Infection

    by Elliot Mathieu, Quentin Marquant, Florian Chain, Edwige Bouguyon, Vinciane Saint-Criq, Ronan Le-Goffic, Delphyne Descamps, Philippe Langella, Thomas A. Tompkins, Sylvie Binda, et al.

    Microbiota studies have dramatically increased over these last two decades, and the repertoire of microorganisms with potential health benefits has been considerably enlarged. The development of next generation probiotics from new bacterial candidates is a long-term strategy that may be more efficient and rapid with discriminative in vitro tests. Streptococcus strains have received attention regarding their antimicrobial potential against pathogens of the upper and, more recently, the lower respiratory tracts. Pathogenic bacterial strains, such as non-typable Haemophilus influenzae (NTHi), Pseudomonas aeruginosa (P. aeruginosa) and Staphylococcus aureus (S. aureus), are commonly associated with acute and chronic respiratory diseases, and it could be interesting to fight against pathogens with probiotics. In this study, we show that a Streptococcus mitis (S. mitis) EM-371 strain, isolated from the buccal cavity of a human newborn and previously selected for promising anti-inflammatory effects, displayed in vitro antimicrobial activity against NTHi, P. aeruginosa or S. aureus. However, the anti-pathogenic in vitro activity was not sufficient to predict an efficient protective effect in a preclinical model. Two weeks of treatment with S. mitis EM-371 did not protect against, and even exacerbated, NTHi lung infection.


  • Open Access

    Host succinate inhibits influenza virus infection through succinylation and nuclear retention of the viral nucleoprotein

    by Antoine Guillon, Deborah Brea‐Diakite, Adeline Cezard, Alan Wacquiez, Thomas Baranek, Jérôme Bourgeais, Frédéric Picou, Virginie Vasseur, Léa Meyer, Christophe Chevalier, et al.

    Influenza virus infection causes considerable morbidity and mortality, but current therapies have limited efficacy. We hypothesized that investigating the metabolic signaling during infection may help to design innovative antiviral approaches. Using bronchoalveolar lavages of infected mice, we here demonstrate that influenza virus induces a major reprogramming of lung metabolism. We focused on mitochondria‐derived succinate that accumulated both in the respiratory fluids of virus‐challenged mice and of patients with influenza pneumonia. Notably, succinate displays a potent antiviral activity in vitro as it inhibits the multiplication of influenza A/H1N1 and A/H3N2 strains and strongly decreases virus‐triggered metabolic perturbations and inflammatory responses. Moreover, mice receiving succinate intranasally showed reduced viral loads in lungs and increased survival compared to control animals. The antiviral mechanism involves a succinate‐dependent posttranslational modification, that is, succinylation, of the viral nucleoprotein at the highly conserved K87 residue. Succinylation of viral nucleoprotein altered its electrostatic interactions with viral RNA and further impaired the trafficking of viral ribonucleoprotein complexes. The finding that succinate efficiently disrupts the influenza replication cycle opens up new avenues for improved treatment of influenza pneumonia.